

## ARTICLE OPEN



# Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases

Regina H. Reynolds<sup>1,2,13</sup>, Aaron Z. Wagen<sup>1,3,4,13</sup>, Frida Lona-Durazo<sup>5,6</sup>, Sonja W. Scholz<sup>7,8</sup>, Maryam Shoi<sup>9,10</sup>, John Hardy<sup>2,9,10</sup>, Sarah A. Gagliano Taliun<sup>5,11</sup> and Mina Ryten<sup>1,2,12</sup>

Genetic correlation ( $r_g$ ) between traits can offer valuable insight into underlying shared biological mechanisms. Neurodegenerative diseases overlap neuropathologically and often manifest comorbid neuropsychiatric symptoms. However, global  $r_g$  analyses show minimal  $r_g$  among neurodegenerative and neuropsychiatric diseases. Importantly, local  $r_g$  s can exist in the absence of global relationships. To investigate this possibility, we applied LAVA, a tool for local  $r_g$  analysis, to genome-wide association studies of 3 neurodegenerative diseases (Alzheimer's disease, Lewy body dementia and Parkinson's disease) and 3 neuropsychiatric disorders (bipolar disorder, major depressive disorder and schizophrenia). We identified several local  $r_g$  s missed in global analyses, including between (i) all 3 neurodegenerative diseases and schizophrenia and (ii) Alzheimer's and Parkinson's disease. For those local  $r_g$  s identified in genomic regions containing disease-implicated genes, such as *SNCA*, *CLU* and *APOE*, incorporation of expression quantitative trait loci identified genes that may drive genetic overlaps between diseases. Collectively, we demonstrate that complex genetic relationships exist among neurodegenerative and neuropsychiatric diseases, highlighting putative pleiotropic genomic regions and genes. These findings imply sharing of pathogenic processes and the potential existence of common therapeutic targets.

npj Parkinson's Disease (2023)9:70; <https://doi.org/10.1038/s41531-023-00504-1>

## INTRODUCTION

Neurodegenerative diseases are a group of syndromically-defined disorders that are characterised by the progressive loss of the structure and function of the central nervous system. They are typically grouped by their predominant neuropathological protein deposit (e.g. synucleinopathies, like Parkinson's disease and Lewy body dementia, by  $\alpha$ -synuclein deposition and Alzheimer's disease by deposition of amyloid), but more often than not, they present with co-pathologies, suggesting that they might share common pathogenic pathways<sup>1,2</sup>. This notion is supported by genome-wide association studies (GWASs), which have (i) identified shared risk loci across neurodegenerative diseases, such as *APOE* and *BIN1* in Alzheimer's disease (AD) and Lewy body dementia (LBD), or *GBA*, *SNCA*, *TMEM175* in Parkinson's disease (PD) and LBD and (ii) demonstrated that genetic risk scores derived from one neurodegenerative disease can predict risk of another, as with AD and PD scores predicting risk of LBD<sup>3-5</sup>. The importance of identifying common pathogenic processes cannot be overstated, given the implications for our mechanistic understanding of these diseases as well as identification of common therapeutic targets benefitting a wider range of patients.

From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality, present as highly heterogenous diseases, with symptoms spanning multiple domains including neuropsychiatric symptoms<sup>6,7</sup>.

Indeed, a higher prevalence of depression has been observed in individuals with dementia compared to those without dementia<sup>8</sup>. Furthermore, depression and anxiety are more common in individuals with PD compared to the general population, with clinically significant symptoms in 30–35% of patients<sup>9,10</sup>. A similar (albeit reversed) phenomenon has been observed in some neuropsychiatric disorders, with a higher risk of dementia diagnoses observed in individuals with schizophrenia (SCZ) versus individuals without a history of serious mental illness<sup>11,12</sup> and a higher risk of PD in individuals diagnosed with depressive disorder in mid or late life<sup>10,13,14</sup>. Together, these observations suggest the possibility of intersecting pathways between neurodegenerative and neuropsychiatric diseases.

Given these clinical and neuropathological overlaps, genetic overlaps would also be expected. However, a study of global genetic correlation between neurological phenotypes demonstrated limited overlap between individual neurodegenerative diseases as well as between neurodegenerative diseases and neuropsychiatric disorders<sup>15,16</sup>. Genetic correlation ( $r_g$ ) is a frequently used measure of genetic overlap, which is traditionally studied on a genome-wide scale, and thus, represents an average of the shared genetic effects across all causal loci in the genome<sup>17</sup>. This global approach may not capture shared genetic effects that are confined to particular regions of the genome (i.e. local  $r_g$  s) or local  $r_g$  s that have opposing directions across the genome<sup>15,17</sup>. Indeed, local  $r_g$  s have been observed between neuropsychiatric

<sup>1</sup>Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London, UK. <sup>2</sup>Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA. <sup>3</sup>Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, London, UK. <sup>4</sup>Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, UK. <sup>5</sup>Montréal Heart Institute, Montréal, QC, Canada. <sup>6</sup>Faculty of Medicine, Université de Montréal, Montréal, Canada. <sup>7</sup>Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA. <sup>8</sup>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA. <sup>9</sup>Department of Neurodegenerative Diseases, Queen Square Institute of Neurology, University College London, London, UK. <sup>10</sup>UK Dementia Research Institute, University College London, London, UK. <sup>11</sup>Department of Medicine & Department of Neurosciences, Université de Montréal, Montréal, QC, Canada. <sup>12</sup>NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, London, UK. <sup>13</sup>These authors contributed equally: Regina H. Reynolds, Aaron Z. Wagen. ✉email: [regina.reynolds.16@ucl.ac.uk](mailto:regina.reynolds.16@ucl.ac.uk); [mina.ryten@ucl.ac.uk](mailto:mina.ryten@ucl.ac.uk)

traits<sup>18</sup> and between AD and PD (specifically in the *HLA*<sup>19</sup> and *MAPT* loci<sup>20</sup>). In addition, previous work using approaches that can detect polygenic overlap (including overlaps where there are mixed patterns of allelic effect directions) have demonstrated a global polygenic overlap between neurodegenerative and neuropsychiatric diseases, such as AD and bipolar disorder (BIP)<sup>21</sup>, AD and major depressive disorder (MDD)<sup>22,23</sup>, and PD and SCZ<sup>24</sup>. Collectively, these studies indicate that local genetic overlaps likely exist between neurodegenerative and neuropsychiatric diseases.

Here, we assess local  $r_g$  between 3 neurodegenerative diseases (AD, LBD and PD) and 3 neuropsychiatric disorders (BIP, MDD and SCZ). All 6 disease traits represent globally prevalent diseases<sup>25</sup>, have reasonably large GWAS cohorts<sup>3,5,26–30</sup>, and importantly, have demonstrated evidence of a potential genetic overlap (but have not, to our knowledge, been systematically assessed all together for local  $r_g$ ). To estimate local  $r_g$  from GWAS summary statistics, we used the recently developed tool local analysis of [co] variant association (LAVA)<sup>31</sup>. Unlike existing tools, such as rho-HESS<sup>32</sup> and SUPERGNOVA<sup>33</sup>, which only permit testing of local  $r_g$  between two traits, LAVA is additionally able to model local genetic relations using more than two traits simultaneously, thus permitting exploration of local conditional genetic relations between multiple traits (a particularly useful feature in the context of neurodegenerative diseases like LBD, which has been hypothesised to lie on a disease continuum between AD and PD<sup>5,34</sup>). In addition, we use data from blood- and brain-derived gene expression traits, in the form of expression quantitative loci (eQTLs), to facilitate functional interpretation of local  $r_g$  between disease traits.

## RESULTS

### Local analyses reveal genetic correlations among neurodegenerative and neuropsychiatric diseases

We applied LAVA to 3 neurodegenerative diseases (AD, LBD and PD) and 3 neuropsychiatric disorders (BIP, MDD and SCZ) (Table 1), all of which represent globally prevalent diseases<sup>25</sup>. Among neurodegenerative diseases, AD and PD are the most common, with a global prevalence of 8.98% and 1.12% in individuals >70 years of age<sup>6,7,25</sup> and consequently, have large GWAS cohorts (AD,  $N$  cases = 71,880; PD,  $N$  cases = 33,674)<sup>3,26</sup>. LBD is the second most common dementia subtype after AD, affecting between 4.2 and 30% of dementia patients<sup>35</sup>. As such, the LBD GWAS cohort is small ( $N$  cases = 2591), but unlike AD and PD neurodegenerative GWASs, 69% of the cohort is pathologically defined<sup>5</sup>. Among neuropsychiatric disorders, MDD is the second most prevalent, with an estimated 185 million people affected globally (equivalent to 2.49% of the general population), while BIP and SCZ have a prevalence of 0.53% and 0.32%, respectively<sup>25</sup>. Accordingly, all 3 disorders have large, well-powered GWASs (BIP,  $N$  cases = 41,917; MDD,  $N$  cases = 170,756; SCZ,  $N$  cases = 40,675)<sup>28–30</sup>.

We tested pairwise local genetic correlations ( $r_g$  s) across a targeted subset of 300 local autosomal genomic regions that contain genome-wide significant GWAS loci from at least one trait (Supplementary Fig. 1, Supplementary Table 1). These genomic regions, henceforth referred to as linkage disequilibrium (LD) blocks, were filtered from the original 2,495 LD blocks generated by Werme et al.<sup>31</sup> using a genome-wide partitioning algorithm that aims to reduce LD between LD blocks.

First, we performed a univariate test for every disease trait at each of the 300 LD blocks to ensure sufficient local genetic signal was present to proceed with bivariate local  $r_g$  analyses. Pairs of traits exhibiting a univariate local genetic signal of  $p < 0.05/300$  were carried forward to bivariate tests, resulting in 1603 bivariate tests across 275 distinct LD blocks. Using a Bonferroni-corrected

$p$  value threshold of  $p < 0.05/1603$ , we detected 77 significant bivariate local  $r_g$  s across 59 distinct LD blocks, with 25 local  $r_g$  s between trait pairs where no significant global  $r_g$  was observed (Fig. 1a, b, Supplementary Tables 2, 3). These 25 correlations included: (i) local  $r_g$  s between all 3 neurodegenerative diseases and SCZ; (ii) a local  $r_g$  between PD and BIP; and (iii) 20 local  $r_g$  s between AD and PD. For 30 of the 77 local  $r_g$  s, the genetic signal of both disease traits may overlap entirely, as suggested by the upper limit of the 95% confidence interval (CI) for explained variance (i.e.  $r^2$ , the proportion of variance in genetic signal of one disease trait in a pair explained by the other) including 1. Notably, the trait pairs where the upper limit of the 95% CI did not include 1 all involved at least one neurodegenerative disease, with the one exception being a local  $r_g$  between PD and SCZ, suggesting that the genetic overlap between neurodegenerative diseases is smaller than between neuropsychiatric disorders in the tested LD blocks (Fig. 1c).

We found no overlap between local  $r_g$  s from our study and local genetic associations reported using rho-HESS, a tool for local  $r_g$  estimation<sup>19</sup>. Furthermore, we found no overlap between local  $r_g$  s from our study and shared genetic loci identified using the conditional/conjunctional false discovery rate (FDR) approach<sup>21,23,24</sup>, a tool for the estimation of global polygenic overlap (Supplementary Note, Supplementary Table 4). We did, however, demonstrate an overlap between local  $r_g$  s from our study and local  $r_g$  s reported using LAVA in a study of 10 psychiatric disorders and 10 substance abuse phenotypes<sup>18</sup>. Between the two studies, we were able to replicate 5 of the 7 overlapping local  $r_g$  s (BIP and SCZ in LD block 457; SCZ and BIP or MDD in LD block 951; MDD and SCZ in LD block 952; and BIP and SCZ in LD block 2483; Supplementary Note; Supplementary Fig. 2; Supplementary Table 4).

### Local analyses associate disease-implicated genomic regions with previously unrelated traits

Across the 77 local  $r_g$  s, 22 involved trait pairs where both traits had genome-wide significant single nucleotide polymorphisms (SNPs) overlapping the LD block tested, 35 involved trait pairs where one trait in the pair had genome-wide significant SNPs overlapping the LD block tested and 20 involved trait pairs where neither trait had genome-wide significant SNPs overlapping the LD block tested (Fig. 2a). Thus, despite the targeted nature of our approach (which biased analyses towards LD blocks that contain genome-wide significant GWAS SNPs), 71% of the detected local  $r_g$  s linked genomic regions implicated by one of the six disease traits with seemingly unrelated disease traits.

For example, LD block 1719 (chr11:112,755,447–113,889,019) and 2281 (chr18:52,512,524–53,762,996) both contained genome-wide significant GWAS SNPs from MDD and SCZ, an overlap which was mirrored by a significant local  $r_g$  between MDD and SCZ (Fig. 2b). In addition, both LD blocks implicated disease traits that did not have overlapping genome-wide significant GWAS SNPs in the region, indicating unexplored disease trait associations. These included (i) LBD in LD block 1719 (chr11:112,755,447–113,889,019), which negatively correlated with SCZ ( $\rho = -0.65$ ,  $p = 4.72 \times 10^{-6}$ ) and (ii) AD and PD, which were positively correlated in LD block 2281 (chr18:52,512,524–53,762,996,  $\rho = 0.41$ ,  $p = 1.24 \times 10^{-8}$ ). Notably, both LD blocks contain genes of interest to traits implicated by local  $r_g$  analyses, including *DRD2* in LD block 1719 (encodes dopamine receptor D2, a target of drugs used in both PD<sup>7</sup> and SCZ treatment<sup>36</sup>) and *RAB27B* in LD block 2281 (encodes Rab27b, a Rab GTPase recently implicated in  $\alpha$ -synuclein clearance<sup>37</sup>).

Local  $r_g$  analyses also highlighted relationships between neurodegenerative traits in regions containing well-known, disease-implicated genes, such as: (i) *SNCA* (implicated in monogenic and sporadic forms of PD<sup>3,5</sup>) in LD block 681

**Table 1.** Overview of traits included in this study.


Trait type	Trait	Abbreviation	N	N cases	N controls	Chr	Global $h^2$ (SE)	$h^2$ Z-score	Original study
Disease	Alzheimer's disease Clinically diagnosed + UK Biobank proxy cases and controls	AD	455,258	71,880 (46,613 proxy)	383,378 (318,246 UK Biobank)	1-22	1.5% (0.2)	7.14	Jansen et al. <sup>26</sup>
Disease	Alzheimer's disease Clinically diagnosed	AD (no proxy)	63,926	21,982	41,944	1-22	7.1% (1.1)	6.25	Kunkle et al. <sup>27</sup>
Disease	Bipolar disorder Clinically diagnosed + UK Biobank self-report during interview with nurse <sup>a</sup>	BIP	413,466	41,917 (1116 self-report)	371,549 (58,113 UK Biobank)	1-22	7.1% (0.3)	26.2	Mullins et al. <sup>28</sup>
Disease	Lewy body dementia Autopsy-confirmed + clinically diagnosed	LBD	6618	2591 (1789 autopsy-confirmed)	4,027	1-22	17.1% (7.6)	2.27	Chia et al. <sup>5</sup>
Disease	Major depressive disorder excluding 23andMe Clinically diagnosed (33 PGC cohorts) + UK Biobank broad depression phenotype <sup>b</sup>	MDD	500,199	170,756 (127,552 UK Biobank broad depression)	329,443 (233,763 UK Biobank)	1-22	6% (0.2)	26	Howard et al. <sup>29</sup>
Disease	Parkinson's disease excluding 23andMe Clinically diagnosed + UK Biobank proxy cases and controls	PD	482,730	33,674 (18,618 proxy)	449,056 (436,419 UK Biobank)	1-22	1.9% (0.2)	10.9	Nalls et al. <sup>3</sup>
Disease	Parkinson's disease excluding 23andMe Clinically diagnosed	PD (no proxy)	27,693	15,056	12,637	1-22	30.6% (2.8)	11.1	Nalls et al. <sup>3</sup>
Disease	Schizophrenia Clinically diagnosed	SCZ	105,318	40,675	64,643	1-22, X	41% (1.4)	29.7	Pardiñas et al. <sup>30</sup>
Gene expression	eQTLGen Blood-derived eQTLs	eQTLGEN	31,684	-	-	1-22	-	-	Vosä et al. <sup>42</sup>
Gene expression	PsychENCODE Brain-derived eQTLs	PSYCHENCODE	1387	-	-	1-22	-	-	Wang et al. <sup>43</sup>

Global observed-scale SNP heritability ( $h^2$ ) for each trait computed using LDSC<sup>66</sup> assuming a continuous liability (which may differ from liability scale  $h^2$  estimates). The  $h^2$  Z-score was calculated by dividing the global  $h^2$  estimate by its standard error (SE).

Chr chromosome.

<sup>a</sup>UK Biobank participants were classified as having bipolar disorder if they had a reported clinical diagnosis of bipolar disorder ( $N = 777$ ) or if they self-reported bipolar disorder during an interview with a nurse at baseline recruitment ( $N = 1116$ ; union  $N = 1454$ ).


<sup>b</sup>UK Biobank broad depression determined by the participants' response at recruitment to the question: "Have you ever seen a GP/psychiatrist for nerves, anxiety, tension or depression?"



**Fig. 1 Overview of local and global genetic correlations between neurodegenerative diseases and neuropsychiatric disorders.** **a** Chord diagram showing the number of significant bivariate local  $r_g$ s ( $p < 0.05/1603$ ) between each of the disease traits across all LD blocks. Positive and negative correlations are coloured red and blue, respectively. **b** Comparison between the global  $r_g$ s estimated by LDSC (bottom) and the mean local  $r_g$  from LAVA (top) across all tested LD blocks. Significant global  $r_g$ s ( $p < 0.05/15$ ) are indicated with \*. The number of significant local  $r_g$ s is indicated by a number in each tile. **c** Bar plot showing the number of significant local  $r_g$ s between disease trait pairs. The fill of the bars indicates the number of significant LD blocks for which the upper limit of the  $r^2$  95% confidence interval (CI) included 1.

(chr4:90,236,972-91,309,863), where a negative local  $r_g$  was observed between AD and PD ( $\rho = -0.41$ ,  $p = 6.51 \times 10^{-13}$ ); (ii) *CLU* (associated with sporadic AD<sup>26,38</sup>) in LD block 1273 (chr8:27,406,512-28,344,176), where a positive local  $r_g$  was observed between AD and PD ( $\rho = 0.36$ ,  $p = 8.76 \times 10^{-12}$ ); and finally, (iii) *APOE* ( $\epsilon 4$  alleles associated with increased AD risk<sup>39</sup>) in LD block 2351 (chr19:45,040,933-45,893,307), where  $r_g$ s were observed between LBD and both AD and PD (LBD-AD:  $\rho = 0.59$ ,  $p = 1.24 \times 10^{-139}$ ; LBD-PD:  $\rho = -0.29$ ,  $p = 2.75 \times 10^{-7}$ ) (Fig. 2c). We also noted a positive correlation between AD and PD in LD

block 2128 (chr16:29,043,178-31,384,210), which contains the AD-associated *KAT8* locus<sup>26</sup> and the PD-associated *SETD1A* locus<sup>3</sup> (of note, rare loss-of-function variants in *SETD1A* are associated with schizophrenia<sup>40</sup>). Given concerns that UK Biobank (UKBB) by-proxy cases could potentially be misdiagnosed (particularly in AD<sup>41</sup>), resulting in spurious  $r_g$ s between AD and PD, we performed sensitivity analyses using GWASs for AD and PD that excluded UKBB by-proxy cases, the results of which indicated this was not the case (Supplementary Fig. 3, Supplementary Table 5, Supplementary Note).



**Fig. 2** Local analyses associate disease-implicated genomic regions with previously unrelated traits. **a** Bar plot (left) showing the number of traits within trait pairs demonstrating significant local  $r_g$  s that had genome-wide significant SNPs overlapping the tested LD block (as illustrated by the schematic on the right). **b** Two LD blocks illustrating the situations depicted in (a). Edge diagrams for each LD block show the standardised coefficient for  $r_g$  ( $\rho$ ) for each significant bivariate local  $r_g$ . Significant negative and positive  $r_g$  s are indicated by blue and red colour, respectively. **c** Heatmaps show the  $\rho$  for each bivariate local  $r_g$  within the LD block. Asterisks (\*) indicate  $r_g$  s that were replicated when using AD and PD GWASs that excluded UK Biobank by-proxy cases. Significant negative and positive  $r_g$  s are indicated by blue and red fill, respectively. Non-significant  $r_g$  s have a grey fill. In both (b, c) panels are labelled by the LD block identifier, the traits with genome-wide significant SNPs overlapping the LD block (indicated in the brackets) and the genomic coordinates of the LD block (in the format chromosome:start-end, GRCh37).

### Local heritability of Lewy body dementia in an APOE-containing LD block is only partly explained by Alzheimer's disease and Parkinson's disease


Eleven LD blocks were associated with >1 trait pair, of which 8 LD blocks had a trait in common across multiple trait pairs. In other words, the genetic component of one disease trait (the outcome trait) could be modelled using the genetic components of multiple predictor disease traits. To explore the independent effects of predictor traits on the outcome trait, as well as potential confounding between predictors, we applied local multiple regression.

A total of 14 multivariate models were run across all 8 LD blocks. In 2 of these models, all predictor traits were found to significantly (and by extension, independently) contribute to the local heritability of the outcome trait (Fig. 3a, Supplementary Table 6). For example, in the APOE-containing LD block 2351 (chr19:45,040,933-45,893,307), fitting a conditional model that included both AD and PD as predictor traits of LBD demonstrated that both independently contributed to the genetic signal of LBD.

In 4 models, only one predictor trait was significant, suggesting that one predictor may account for the relationship of the outcome trait with other non-significant predictors (Fig. 3a, Supplementary Table 6). In the remaining 8 models, all predictor traits were non-significant, despite significant bivariate correlations, which could indicate collinearity between predictors (Supplementary Fig. 4). Examples of the latter two situations (i.e. 0 or 1 significant predictor trait) are given in the Supplementary Note.

We noted that all models with a neuropsychiatric outcome trait and neuropsychiatric predictor traits had a high multivariate  $r^2$  (range: 0.53-1), with upper confidence intervals including 1 (Fig. 3b), suggesting that the genetic signal of the neuropsychiatric outcome trait could be entirely explained by its predictor traits in these LD blocks. In contrast, in LD block 2351, the multivariate  $r^2$  was 0.43 (95% CI: 0.38 to 0.5), a result that held using GWASs for AD and PD that excluded by-proxy cases ( $r^2 = 0.49$ , 95% CI: 0.44 to 0.57; Supplementary Fig. 3). Thus, while AD and PD jointly explained approximately 40% of the local heritability of LBD, a proportion of the local heritability for LBD was independent of AD and PD.





**Fig. 3 Multiple regression across LD blocks with multiple trait pair correlations.** For both plots, only those multiple regression models with at least one significant predictor ( $p < 0.05$ ) are shown (for models where all predictors were non-significant, see Supplementary Fig. 4). **a** Plots of standardised coefficients for each predictor in multiple regression models across each LD block, with whiskers spanning the 95% confidence interval for the coefficients. Panels are labelled by the LD block identifier and the regression model. **b** Multivariate  $r^2$  for each LD block and model, where multivariate  $r^2$  represents the proportion of variance in genetic signal for the outcome trait explained by all predictor traits simultaneously. Whiskers span the 95% confidence interval for the  $r^2$ . \*\*\* $p < 0.001$ ; \*\* $p < 0.01$ ; \* $p < 0.05$ . Coordinates for LD blocks (in the format chromosome:start-end, GRCh37): 952, chr6:27,261,036-28,666,364; 2001, chr14:71,140,427-72,665,319; 2117, chr16:12,793,150-13,893,407; 2281, chr18:52,512,524-53,762,996; 2351, chr19:45,040,933-45,893,307.

### Incorporation of gene expression traits to facilitate functional interpretation of disease trait correlations


To dissect whether regulation of gene expression might underlie local  $r_g$ s between disease traits, we performed local  $r_g$  analyses using expression quantitative trait loci (eQTLs) from eQTLGen<sup>42</sup> and PsychENCODE<sup>43</sup>, which represent large human blood and brain expression datasets, respectively (Table 1). We used LAVA to study relationships between gene expression and disease traits on account of its ability to model the uncertainty in eQTL effect estimates (unlike the commonly used TWAS framework, which as a result, has an increased type 1 error rate<sup>44</sup>). In addition, where three-way relationships were observed between 2 disease traits and an eQTL, we computed partial correlations to determine whether correlations between disease traits could be explained by the eQTL.

We restricted analyses to the 5 LD blocks highlighted in Fig. 2 (LD block 681, chr4:90,236,972-91,309,863; LD block 1273, chr8:27,406,512-28,344,176; LD block 1719, chr11:112,755,447-113,889,019; LD block 2281, chr18:52,512,524-53,762,996; LD block 2351, chr19:45,040,933-45,893,307), which contained genes of

interest to at least one of the disease traits implicated by local  $r_g$  analyses. From these LD blocks of interest, we defined genic regions (gene start and end coordinates  $\pm 100$  kb) for all overlapping protein-coding, antisense or lincRNA genes ( $n = 92$ ).

We detected a total of 135 significant bivariate local  $r_g$ s across 47 distinct genic regions (FDR  $< 0.05$ ), with 43 local  $r_g$ s across 27 distinct genic regions between trait pairs involving a disease trait and a gene expression trait (Supplementary Fig. 5, Supplementary Table 7). We noted that the explained variance ( $r^2$ ) between trait pairs involving a disease trait and a gene expression trait tended to be lower than between trait pairs involving two disease traits (Supplementary Fig. 6), an observation that aligns with a recent study that found only 11% of trait heritability to be mediated by bulk-tissue gene expression<sup>45</sup>.

With the exception of the *SNCA*-containing LD block 681 (chr4:90,236,972-91,309,863), where eQTLs for only 1 out of 5 genes tested in the block were correlated with a disease trait (negative  $r_g$  between blood-derived *SNCA* eQTLs and PD), the expression of multiple genes was associated with disease traits across the remaining LD blocks (Fig. 4a). In addition, the



expression of several genes was associated with more than one disease trait (Fig. 4b). For example, blood- and brain-derived ANKK1 eQTLs (*DRD2*-containing LD block 1719, chr11:112,755,447-113,889,019) were negatively correlated with both MDD and SCZ, which themselves were positively correlated (Fig. 4c). A SNP

residing in the coding region of ANKK1 (rs1800497, commonly known as TaqIA SNP) has been previously associated with alcoholism, schizophrenia and eating disorders, although it is unclear whether this SNP exerts its effect via *DRD2* or ANKK1<sup>46</sup>. Conditioning the local  $r_g$  between MDD and SCZ on ANKK1 eQTLs

**Fig. 4 Incorporation of gene expression traits to facilitate functional interpretation of disease trait correlations.** **a** Bar plot of the number of eQTL genes (as defined by their genic regions) tested in each LD block. The fill of the bars indicates whether eQTL genes were significantly correlated with at least one disease trait. **b** Bar plot of the number of eQTL genes that were significantly correlated with at least one disease trait. The fill of the bars indicates whether eQTL genes in local  $r_g$  s were correlated with one or more disease traits. **c, d, f** Heatmaps of the standardised coefficient for  $r_g$  ( $\rho$ ) for each significant gene expression-disease trait correlation (FDR < 0.05) within LD block (**c**) 1719, (**d**) 1273 and (**f**) 2351. Genes are ordered left to right on the x-axis by the genomic coordinate of their gene start. Panels are labelled by the eQTL dataset from which eQTL genes were derived (either PsychENCODE's analysis of adult brain tissue from 1387 individuals or the eQTLGen meta-analysis of 31,684 blood samples from 37 cohorts). **e** Edge diagrams for representative genic regions show the  $\rho$  for each significant bivariate local  $r_g$  (FDR < 0.05). GWAS and eQTL nodes are indicated by grey and white fill, respectively. Panels are labelled by the gene tested and the eQTL dataset from which eQTL genes were derived. In (**c–f**) significant negative and positive  $r_g$  s are indicated by blue and red colour, respectively. Coordinates for LD blocks (in the format chromosome:start-end, GRCh37): 681, chr4:90,236,972-91,309,863; 1273, chr8:27,406,512-28,344,176; 1719, chr11:112,755,447-113,889,019; 2281, chr18:52,512,524-53,762,996; 2351, chr19:45,040,933-45,893,307.

weakened the strength and significance of the  $r_g$ , suggesting that the shared risk of MDD and SCZ in the overlapping *ANKK1* and *DRD2* genic regions may be partly driven by *ANKK1* gene expression (eQTLGen: MDD~SCZ,  $r_g = 0.72$ ,  $p = 0.000132$ ; MDD~SCZ|*ANKK1*,  $r_g = 0.60$ ,  $p = 0.0203$ ; PsychENCODE: MDD~SCZ,  $r_g = 0.67$ ,  $p = 0.000271$ ; MDD~SCZ|*ANKK1*,  $r_g = 0.61$ ,  $p = 0.00441$ ; Supplementary Table 9).

A high degree of eQTL sharing across disease traits was observed in the *CLU*-containing LD block 1273 (chr8:27,406,512-28,344,176), with blood-derived eQTLs from 5 out of the 6 genes implicated in local  $r_g$  s found to correlate with both AD and PD (Fig. 4b, d). This included situations where eQTL-disease trait correlations had (i) the same direction of effect across both disease traits (as observed with *PBK*, *PNOG* and *SCARA5*) or (ii) opposing directions of effect across both disease traits (as observed with *CLU* and *ESCO2*) (Fig. 4d). Notably, while a significant positive local  $r_g$  was observed between AD and PD in the *PBK* and *SCARA5* genic regions (reflecting the positive local  $r_g$  observed between AD and PD across the entire LD block), no local  $r_g$  was observed between AD and PD in the *CLU* genic region, suggesting that the shared risk of AD and PD in LD block 1273 may be driven by the expression of genes other than the AD-associated *CLU* (Fig. 4e). Indeed, while conditioning the local  $r_g$  between AD and PD on *SCARA5* eQTLs had little effect on the strength and significance of the correlation (AD~PD,  $r_g = 0.16$ ,  $p = 0.000135$ ; AD~PD |*SCARA5*,  $r_g = 0.15$ ,  $p = 0.000487$ ; Supplementary Table 9), the local  $r_g$  between AD and PD was weakened and no longer significant after conditioning on *PBK* eQTLs, indicating the *PBK* eQTLs may partly explain the local  $r_g$  between AD and PD (AD~PD,  $r_g = 0.14$ ,  $p = 0.0187$ ; AD~PD |*PBK*,  $r_g = 0.07$ ,  $p = 0.259$ ; Supplementary Table 9).

Compared to LD block 1273, the degree of eQTL sharing across disease traits was lower in the *APOE*-containing LD block 2351 (chr19:45,040,933-45,893,307), with eQTLs from 4 out of 16 genes implicated in local  $r_g$  s found to correlate with AD and one of PD or LBD (Fig. 4b, f). Shared eQTL genes were only observed in blood and included *BCL3*, *CLPTM1*, *PVRL2* and *TOMM40*, with expression of *BCL3* and *CLPTM1* positively correlating with AD and PD and expression of *PVRL2* and *TOMM40* positively correlating with AD and LBD. As the exception, *PVR* eQTLs were negatively associated with both AD and PD albeit in different tissues: AD in brain and PD in blood. Expression of the remaining 11 genes was exclusively associated with either AD ( $n = 8$ ) or PD ( $n = 3$ ). No significant local  $r_g$  was observed between *APOE* eQTLs and AD (FDR < 0.05), although a nominal positive  $r_g$  was observed in blood ( $\rho = 0.178$ ,  $\rho$  CI = 0.007 to 0.352,  $p = 0.039$ ; Supplementary Fig. 5e, Supplementary Table 7). Overall, these results indicate that risk of neurodegenerative diseases (in particular, AD) is associated with expression of multiple genes in the *APOE*-containing LD block. Further, they add to a growing body of evidence suggesting that in parallel with the well-studied *APOE-ε4* risk allele, there are additional *APOE*-independent risk factors in the region (such as *BCL3*<sup>47</sup> and *PVRL2*<sup>48</sup>) that may contribute to AD risk.

For a complete overview of all genic regions tested across the 5 LD blocks of interest, see Supplementary Fig. 5 and Supplementary Table 7.

## DISCUSSION

Despite clinical and neuropathological overlaps between neurodegenerative diseases, global analyses of genetic correlation ( $r_g$ ) show minimal  $r_g$  among neurodegenerative diseases or across neurodegenerative and neuropsychiatric diseases. However, local  $r_g$  s can deviate from the genome-wide average estimated by global analyses and may even exist in the absence of a genome-wide  $r_g$ , thus motivating the use of tools to model local genetic relations.

Here, we applied LAVA to 3 neurodegenerative diseases and 3 neuropsychiatric disorders to determine whether local  $r_g$  s exist in a subset of 300 LD blocks that contain genome-wide significant GWAS loci from at least one of six investigated disease traits. We identified 77 significant bivariate local  $r_g$  s across 59 distinct LD blocks, with 25 local  $r_g$  s between trait pairs where no significant global  $r_g$  was observed, including between (i) all 3 neurodegenerative diseases and SCZ and (ii) AD and PD. Local  $r_g$  s highlighted expected associations (e.g. AD and LBD in the *APOE*-containing LD block 2351<sup>5</sup>, chr19:45,040,933-45,893,307) and putative new associations (e.g. AD and PD in the *CLU*-containing LD block 1273, chr8:27,406,512-28,344,176) in genomic regions containing well-known, disease-implicated genes. Likewise, incorporation of eQTLs confirmed known relationships between diseases and genes, such as the association of AD with *CLU* expression<sup>38</sup> and PD with *SNCA* expression in blood<sup>49</sup>, and revealed putative new disease-gene relationships. Together, these results indicate that more complex aetiological relationships exist between neurodegenerative and neuropsychiatric diseases than those revealed by global  $r_g$  s. Further, they highlight potential gene expression intermediaries that may account for local  $r_g$  s between disease traits.

These findings have important implications for our understanding of neurodegenerative diseases and the extent to which they overlap. An overlap between the synucleinopathies and AD is often acknowledged in the context of LBD, which has been hypothesised to lie on a disease continuum between AD and PD<sup>5,34</sup>. In support of this continuum, LBD was found to associate with both AD and PD in the *APOE*-containing LD block 2351 (chr19:45,040,933-45,893,307). Multiple regression analyses confirmed that AD and PD were significant predictors of LBD heritability in LD block 2351. Importantly, when AD and PD were modelled together, they explained only ~ 40% of the local heritability of LBD in LD block 2351, implying that LBD represents more than the union of AD and PD. Further, the associations of AD and PD with LBD had opposing regression coefficients, suggesting that the contribution of AD and PD to LBD in the *APOE* locus may not be synergistic. This mirrors the observation that genome-wide genetic risk scores of AD and PD do not interact in LBD<sup>5</sup>, and may indicate that different biological pathways underlie the association



between LBD and AD/PD. Indeed, only blood-derived *PVRL2* and *TOMM40* eQTLs were found to correlate with both AD and LBD, while no shared eQTL genes were detected between PD and LBD.

Less acknowledged is the genetic overlap between AD and PD, with no global  $r_g$  reported between the two diseases<sup>16,50</sup> and no significant evidence for the presence of loci that increase the risk of both diseases<sup>51</sup>. As the exception, genetic overlaps have been reported between AD and PD in the *HLA*<sup>19</sup> and *MAPT* loci<sup>20</sup>, hinting that pleiotropy may exist locally. In support of local pleiotropy, we observed 20 local  $r_g$ s between AD and PD in genomic regions containing disease-implicated genes, such as *SNCA* (LD block 681, chr4:90,236,972-91,309,863) and *CLU* (LD block 1273, chr8:27,406,512-28,344,176). In the case of the *CLU*-containing LD block 1273 (chr8:27,406,512-28,344,176), incorporation of eQTLs demonstrated an association of AD and PD with the expression of 5 genes, although partial correlations suggested that only *PBK* expression could explain the correlation between AD and PD. *PBK* encodes a serine-threonine kinase involved in regulation of cellular proliferation and cell-cycle progression<sup>52</sup>, which has been shown to be overexpressed in proliferative cells, including neural precursors cells in the subventricular zone of the adult brain<sup>52,53</sup>. The remaining associations between eQTLs and AD or PD, which included an association between the ferritin receptor *SCARA5*<sup>54</sup> and both AD and PD, appeared to operate independently across diseases. Notably, cellular iron overload and iron-induced oxidative stress have been implicated in several neurodegenerative diseases such as AD and PD<sup>54,55</sup>. In contrast, only blood-derived *SNCA* eQTLs were associated with PD in LD block 681 (chr4:90,236,972-91,309,863), suggesting that the association between AD and PD at the *SNCA* locus could be driven by tissue- or context-dependent gene expression or alternatively other molecular phenotypes.

A few studies have demonstrated genetic overlaps between neurodegenerative and neuropsychiatric diseases, such as AD and BIP<sup>21</sup>, AD and MDD<sup>22,23</sup>, and PD and SCZ<sup>24</sup>, while others have demonstrated no overlap<sup>16,56</sup>, with divergences in outcomes ascribed to differences in methodology and cohort<sup>22</sup>. Here, we observed a local  $r_g$  between BIP and PD, in addition to local  $r_g$ s between schizophrenia and all 3 neurodegenerative diseases, which in the case of LBD was observed in an LD block containing the gene *DRD2* (LD block 1719, chr11:112,755,447-113,889,019). Notably, parkinsonism in dementia with Lewy bodies (DLB, one of the two LBDs), is often less responsive to dopaminergic treatments than in PD<sup>57</sup>. Furthermore, methylation of the *DRD2* promoter in leucocytes has been shown to differ between DLB and PD<sup>58</sup>, while D2 receptor density has been shown to be significantly reduced in the temporal cortex of DLB patients, but not AD<sup>59</sup>, suggesting that the *DRD2* locus may harbour markers that could distinguish between these neurodegenerative diseases. Our study adds to the body of evidence in favour of a shared genetic basis between neurodegenerative and neuropsychiatric diseases, although further work will be required to determine whether this genetic overlap underlies the clinical and epidemiological links observed between these two disease groups.

This study is not without its limitations, with several limitations related to the input data. These limitations include: (i) the variability in cohort size (sample size is a key determinant of the power to detect the association of a variant with a trait), which in the case of the smallest GWAS, LBD, may explain the limited number of local  $r_g$ s observed involving this trait; (ii) the risk of misdiagnosis (particularly in GWASs that include broader definitions of a disorder, such as the MDD GWAS, which includes the UK Biobank broad definition of depression as well as clinically-derived phenotypes for MDD); (iii) the lack of X chromosome in all but one trait (notably, the X chromosome is not only longer than chromosome 8-22, but according to Ensembl v106<sup>60</sup> encodes 858 and 689 protein-coding and non-coding genes, respectively); and (iv) the lack of genetic diversity (i.e. all traits used were

derived from individuals of European ancestry). Given that population-specific genetic risk factors exist, such as the lack of *MAPT* GWAS signal in the largest GWAS of Asian patients with PD<sup>61</sup>, and that transethnic global  $r_g$ s between traits such as gene expression are significantly less than 1<sup>62</sup>, it is imperative that studies of local  $r_g$  are expanded to include diverse populations.

Among methodological limitations, analyses were restricted only to genomic loci with evidence of trait association. Exploring all genomic loci may show further loci of pleiotropy between conditions, but is beyond the scope of the current study. Furthermore, as mentioned by the developers of LAVA<sup>31</sup>, local  $r_g$ s could potentially be confounded by association signals from adjacent genomic regions, a limitation which is particularly pertinent in our analysis of gene expression traits where LD blocks were divided into smaller (often overlapping) genic regions. Additional fine-mapping (both computational and biological) could be helpful in narrowing down the set of potentially causal variants and consequently the genomic regions of interest<sup>63</sup>.

Importantly, as with any genetic correlation analysis, an observed  $r_g$  does not guarantee the presence of true pleiotropy. Spurious  $r_g$ s can occur due to LD or misclassification<sup>17</sup>. Here, we attempted to address the potential misclassification of by-proxy cases via sensitivity analyses using GWASs for AD and PD that excluded UKBB by-proxy cases. We replicated 2 of the 3 significant local  $r_g$ s observed in 2 LD blocks when using GWASs with by-proxy cases (Supplementary Note). However, we were unable to test for local  $r_g$ s across the remaining 19 LD blocks due to insufficient univariate signal, which could reflect (i) a genuine contribution of by-proxy cases to trait  $h^2$  in the region or (ii) a lack of statistical power to detect a genetic signal. Given the substantial decrease in cohort numbers when UKBB by-proxy cases are excluded from AD and PD GWASs (Table 1), a lack of statistical power seems the more likely explanation, warranting a revisit of this analysis as clinically-diagnosed and/or pathologically-defined cohorts increase in size.

Finally, even where observed  $r_g$ s potentially represent true pleiotropy, LAVA cannot discriminate between vertical and horizontal pleiotropy (refs.<sup>17,31</sup>). Thus, while incorporation of gene expression can provide testable hypotheses regarding the underlying genes and biological pathways that drive relationships between neurodegenerative and neuropsychiatric diseases, experimental validation is required to establish the extent to which these genes represent genuine intermediary phenotypes.

In summary, our results have important implications for our understanding of the genetic architecture of neurodegenerative and neuropsychiatric diseases, including the demonstration of local pleiotropy particularly between neurodegenerative diseases. Not only do these findings suggest that neurodegenerative diseases may share common pathogenic processes, highlighting putative gene expression intermediaries which may underlie relationships between diseases, but they also infer the existence of common therapeutic targets across neurodegenerative diseases that could be leveraged for the benefit of broader patient groups.

## METHODS

### Trait pre-processing

Summary statistics from a total of 8 distinct traits were used, including 6 disease traits and 2 gene expression traits. Disease traits included 3 neurodegenerative diseases (Alzheimer's disease, AD; Lewy body dementia, LBD; and Parkinson's disease, PD) and 3 neuropsychiatric disorders (bipolar disorder, BIP; major depressive disorder, MDD; and schizophrenia, SCZ)<sup>3,5,26-30</sup>. Gene expression traits were used to facilitate functional interpretation of local genetic correlations ( $r_g$ ) between disease traits. Gene expression traits included expression quantitative trait loci (eQTLs) from

eQTLGen<sup>42</sup> and PsychENCODE<sup>43</sup>, which represent large human blood and brain expression datasets, respectively. All traits used were derived from individuals of European ancestry. Details of all summary statistics used can be found in Table 1.

Where necessary, SNP genomic coordinates were mapped to Reference SNP cluster IDs (rsIDs) using the SNPlocs.Hsapiens.dbSNP144.GRCh37 package<sup>64</sup>. In the case of the PD GWAS without UK Biobank (UKBB) data (summary statistics were kindly provided by the International Parkinson Disease Genomics Consortium), additional quality control filtering was applied, including removal of SNPs (i) with MAF < 1%, (ii) displaying an  $I^2$  heterogeneity value of  $\geq 80$  and (iii) where the SNP was not present in at least 9 out of the 13 cohorts included in the meta-analysis.

### Global genetic correlation analysis and estimation of sample overlaps

Across disease trait pairs, LD score regression (LDSC) was used to (i) estimate the observed-scale SNP heritability of each trait (which assumes a continuous liability, and thus may differ from liability-scale estimates of SNP heritability), (ii) determine the global  $r_g$  and (iii) estimate sample overlap<sup>65,66</sup>. All disease traits had significant SNP-based heritability ( $Z$ -score > 2) and met with the criteria suggested for reliable estimates of genetic correlation, which include: (i) heritability  $Z$ -score > 1.5 (optimal > 4), (ii) mean Chi square of test statistics > 1.02, and (iii) intercept estimated from SNP heritability analysis is between 0.9 and 1.1<sup>67</sup> (Supplementary Table 2). We note that the heritability  $Z$ -score of LBD was 2.27, which is below the optimal suggested, and as such, can be expected to produce larger standard errors around estimates of global  $r_g$ .

Summary statistics for each trait were pre-processed using LDSC's `munge_sumstats.py` ([https://github.com/bulik/ldsc/blob/master/munge\\_sumstats.py](https://github.com/bulik/ldsc/blob/master/munge_sumstats.py)) together with HapMap Project Phase 3 SNPs<sup>68</sup>. For the LD reference panel, 1000 Genomes Project Phase 3 European population SNPs were used<sup>69</sup>. Both HapMap Project Phase 3 SNPs and European LD Scores from the 1000 Genomes Project are made available by the developers of LDSC<sup>65,66</sup> from the following repository: <https://alkesgroup.broadinstitute.org/LDSCORE/> (see Box 1 for details).

The estimated sample overlap was used as an input for LAVA, given that potential sample overlap between GWASs could impact estimated local  $r_g$ s<sup>31</sup>. Any shared variance due to sample overlap was modelled as a residual genetic covariance. As performed by Werme et al.<sup>31</sup>, a symmetric matrix was constructed, with off-diagonal elements populated by the intercepts for genetic covariance derived from cross-trait LDSC and diagonal elements populated by comparisons of each trait with itself. This symmetric matrix was then converted to a correlation matrix. Importantly, it is not possible to estimate sample overlap with eQTL summary statistics, but given that the cohorts used in the GWASs were different from the cohorts included in the eQTL datasets, we assumed sample overlap between GWASs and eQTL datasets to be negligible. Thus, they were set to 0 in the correlation matrix. However, given the inclusion of GTEx samples in both eQTL datasets and our inability to estimate this overlap, downstream LAVA analyses were performed separately for each eQTL dataset.

### Defining genomic regions for local genetic correlation analysis

*Between disease traits.* Genome-wide significant loci ( $p < 5 \times 10^{-8}$ ) were derived from publicly available AD, BIP, LBD, MDD, PD and SCZ GWASs. Genome-wide significant loci were overlapped with linkage disequilibrium (LD) blocks generated by Werme et al.<sup>31</sup> using a genome-wide partitioning algorithm. Briefly, each chromosome was recursively split into blocks using (i) a break point to minimise LD between the resulting blocks and (ii)

a minimum size requirement. The resulting LD blocks represent approximately equal-sized, semi-independent blocks of SNPs, with a minimum size requirement of 2,500 SNPs (resulting in an average block size of around 1Mb). Only those LD blocks containing genome-wide significant GWAS loci from at least one trait were carried forward in downstream analyses, resulting in a total of 300 autosomal LD blocks. Of the 22 possible autosomes, 21 contained LD blocks with overlapping loci, with the highest number of LD blocks located in chromosome 1 and 6 (Supplementary Fig. 1). LD block locations were in reference to build GRCh37 and are presented in the format: LD block identifier, chromosome:start-end.

*Between disease and gene expression traits.* A total of 5 LD blocks, as highlighted by bivariate local  $r_g$  analysis of disease traits, were used in this analysis (LD block 681, chr4:90,236,972-91,309,863; LD block 1273, chr8:27,406,512-28,344,176; LD block 1719, chr11:112,755,447-113,889,019; LD block 2281, chr18:52,512,524-53,762,996; LD block 2351, chr19:45,040,933-45,893,307). From these LD blocks of interest, we defined genic regions for all protein-coding, antisense or lincRNA genes that overlapped an LD block of interest. Genic regions were defined as the start and end coordinates of a gene (Ensembl v87, GRCh37) with an additional 100 kb upstream and 100 kb downstream of gene start/end coordinates. We included a 100-kb window as most lead *cis*-eQTL SNPs (i.e. the SNP with the most significant  $p$ -value in a SNP-gene association) lie outside the gene start and end coordinates and are located within 100 kb of the gene (in eQTLGen, 55% of lead-eQTL SNPs were outside the gene body and 92% were within 100 kb from the gene<sup>42</sup>). These genic regions ( $n = 92$ ) were carried forward in downstream analyses. For a given genic region, we then used all SNPs for which eQTL summary statistics for the relevant gene were available (e.g. all SNP-gene pairs that relate to *CLU* in the *CLU* genic region).

### Estimating bivariate local genetic correlations

*Between disease traits.* The detection of valid and interpretable local  $r_g$  requires the presence of sufficient local genetic signal. For this reason, a univariate test was performed as a filtering step for bivariate local  $r_g$  analyses. Bivariate local  $r_g$  analyses were only performed for pairs of disease traits which both exhibited a significant univariate local genetic signal ( $p < 0.05/300$ , where the denominator represents the total number of tested LD blocks). This step resulted in a total of 1,603 bivariate tests spanning 275 distinct LD blocks. Bivariate results were considered significant when  $p < 0.05/1603$ .

We compared local  $r_g$ s to existing results from studies of: (i) AD and PD using rho-HESS<sup>19</sup>; (ii) AD and BIP<sup>21</sup>, AD and MDD<sup>23</sup>, PD and SCZ<sup>24</sup>, all of which used a conditional/conjunctional FDR approach (conditional FDR is an extension of the standard FDR method, and re-ranks the test statistics of a primary phenotype based on the strength of the association with a secondary phenotype, while conjunctional FDR is used post-hoc to identify shared genetic loci); and (iii) 10 psychiatric disorders and 10 substance abuse phenotypes using LAVA<sup>18</sup>. For all comparisons, genomic coordinates were used to overlap either SNPs<sup>21,24</sup> or genomic regions<sup>18,19</sup> with LD blocks. SNPs were converted from rsIDs to their GRCh37 genomic coordinates using the SNPlocs.Hsapiens.dbSNP144.GRCh37 package<sup>64</sup>. In all comparisons, local  $r_g$ s from this study were filtered to include only overlapping disease traits. Results are described in the Supplementary Note.

*Between disease and gene expression traits.* For each genic region, only those disease traits that were found to have a significant local  $r_g$  in the associated LD block were carried forward to univariate and bivariate analyses with eQTL summary statistics. As previously described, a univariate test was performed as a filtering step for

**Box 1—key resources**

Resource	Source/Reference	Identifier/URL
Deposited Data		
Ensembl GRCh37 v87	Ensembl genome browser <sup>60</sup>	<a href="http://ftp.ensembl.org/pub/grch37/current/gtf/homo_sapiens/">http://ftp.ensembl.org/pub/grch37/current/gtf/homo_sapiens/</a>
eQTLGen eQTLs	Vosā et al. <sup>42</sup>	<a href="https://www.eqtlgen.org/cis-eqtls.html">https://www.eqtlgen.org/cis-eqtls.html</a>
GWAS, Alzheimer's disease (clinically diagnosed + UK Biobank proxy cases and controls)	Jansen et al. <sup>26</sup>	<a href="https://ctg.cncr.nl/software/summary_statistics">https://ctg.cncr.nl/software/summary_statistics</a>
GWAS, Alzheimer's disease (clinically diagnosed)	Kunkle et al. <sup>27</sup>	<a href="https://www.niagads.org/igap-rv-summary-stats-kunkle-p-value-data">https://www.niagads.org/igap-rv-summary-stats-kunkle-p-value-data</a>
GWAS, Bipolar disease	Mullins et al. <sup>28</sup>	<a href="https://www.med.unc.edu/pgc/download-results/">https://www.med.unc.edu/pgc/download-results/</a>
GWAS, Lewy body dementia	Chia et al. <sup>5</sup>	<a href="https://www.ebi.ac.uk/gwas/studies/GCST90001390">https://www.ebi.ac.uk/gwas/studies/GCST90001390</a>
GWAS, Parkinson's disease excluding 23andMe	Nalls et al. <sup>3</sup>	<a href="https://pdgenetics.org/resources">https://pdgenetics.org/resources</a>
GWAS, Major depressive disorder	Howard et al. <sup>29</sup>	<a href="https://www.med.unc.edu/pgc/download-results/">https://www.med.unc.edu/pgc/download-results/</a>
GWAS, Schizophrenia	Pardiñas et al. <sup>30</sup>	<a href="https://www.med.unc.edu/pgc/download-results/">https://www.med.unc.edu/pgc/download-results/</a>
LAVA LD blocks	Werme et al. <sup>31</sup>	<a href="https://github.com/cadeleeuw/lava-partitioning">https://github.com/cadeleeuw/lava-partitioning</a>
LDSC: HapMap Project Phase 3 SNPs	International HapMap 3 Consortium <sup>68</sup>	<a href="https://alkesgroup.broadinstitute.org/LDSCORE/">https://alkesgroup.broadinstitute.org/LDSCORE/</a> ; file name: w_hm3_snplist
LDSC: 1000 Genomes European LD Scores	1000 Genomes Project Consortium <sup>69</sup>	<a href="https://alkesgroup.broadinstitute.org/LDSCORE/">https://alkesgroup.broadinstitute.org/LDSCORE/</a> ; file name: eur_w_ld_chr.tar.bz2
PsychENCODE eQTLs	Wang et al. <sup>43</sup>	<a href="http://resource.psychencode.org/">http://resource.psychencode.org/</a>
Software		
Bioconductor		
BiocManager (v 1.30.16)	Morgan <sup>71</sup>	<a href="http://www.bioconductor.org/">http://www.bioconductor.org/</a> ; RRID:SCR_006442
CRAN		<a href="https://CRAN.R-project.org/package=BiocManager">https://CRAN.R-project.org/package=BiocManager</a>
circize (v 0.4.13)	Gu et al. <sup>72</sup>	<a href="http://cran.r-project.org/">http://cran.r-project.org/</a> ; RRID:SCR_003005
cowplot (v 1.1.1)	Wilke <sup>75</sup>	<a href="https://github.com/jokergoo/circize">https://github.com/jokergoo/circize</a> ; RRID:SCR_002141
data.table (v 1.14.2)	Dowle and Srinivasan <sup>76</sup>	<a href="https://CRAN.R-project.org/package=cowplot">https://CRAN.R-project.org/package=cowplot</a> ; RRID:SCR_018081
doSNOW (v 1.0.19)	Microsoft and Weston <sup>77</sup>	<a href="https://CRAN.R-project.org/package=data.table">https://CRAN.R-project.org/package=data.table</a>
foreach (v 1.5.1)	Microsoft and Weston <sup>78</sup>	<a href="https://CRAN.R-project.org/package=doSNOW">https://CRAN.R-project.org/package=doSNOW</a>
GenomicRanges (v 1.42.0)	Lawrence et al. <sup>79</sup>	<a href="https://CRAN.R-project.org/package=foreach">https://CRAN.R-project.org/package=foreach</a>
ggbeeswarm (v 0.6.0)	Clarke and Sherrill-Mix <sup>80</sup>	<a href="https://bioconductor.org/packages/release/bioc/html/GenomicRanges.html">https://bioconductor.org/packages/release/bioc/html/GenomicRanges.html</a> ; RRID:SCR_000025
ggplot2 (v 3.3.5)	Wickham <sup>73</sup>	<a href="https://CRAN.R-project.org/package=ggbeeswarm">https://CRAN.R-project.org/package=ggbeeswarm</a>
ggpubr (v 0.4.0)	Kassambara <sup>81</sup>	<a href="https://ggplot2.tidyverse.org/">https://ggplot2.tidyverse.org/</a> ; RRID:SCR_014601
ggraph (v 2.0.5)	Pedersen <sup>74</sup>	<a href="https://CRAN.R-project.org/package=ggpubr">https://CRAN.R-project.org/package=ggpubr</a> ; RRID:SCR_021139
gtools (v 3.9.2)	Warnes et al. <sup>82</sup>	<a href="https://CRAN.R-project.org/package=ggraph">https://CRAN.R-project.org/package=ggraph</a> ; RRID:SCR_021239
here (v 1.0.1)	Müller <sup>83</sup>	<a href="https://CRAN.R-project.org/package=gtools">https://CRAN.R-project.org/package=gtools</a>
janitor (v 2.1.0)	Firke <sup>84</sup>	<a href="https://CRAN.R-project.org/package=here">https://CRAN.R-project.org/package=here</a>
LAVA (v 0.0.6; commit #7be342)	Werme et al. <sup>31</sup>	<a href="https://CRAN.R-project.org/package=janitor">https://CRAN.R-project.org/package=janitor</a>
LDSC (v 1.0.1)	Bulik-Sullivan et al. <sup>66</sup>	<a href="https://github.com/josefin-werme/LAVA">https://github.com/josefin-werme/LAVA</a>
openxlsx (v 4.2.4)	Schauberger and Walker <sup>85</sup>	<a href="https://github.com/bulik/ldsc">https://github.com/bulik/ldsc</a>
qdapTools (v 1.3.5)	Rinker <sup>86</sup>	<a href="https://CRAN.R-project.org/package=openxlsx">https://CRAN.R-project.org/package=openxlsx</a> ; RRID:SCR_019185
readxl (v 1.3.1)	Wickham and Bryan <sup>87</sup>	<a href="http://github.com/trinker/qdapTools">http://github.com/trinker/qdapTools</a>
R (v 4.0.5)	R Core Team <sup>70</sup>	<a href="https://CRAN.R-project.org/package=readxl">https://CRAN.R-project.org/package=readxl</a> ; RRID:SCR_018083
rtracklayer (v 1.50.0)	Lawrence et al. <sup>88</sup>	<a href="http://www.r-project.org/">http://www.r-project.org/</a> ; RRID:SCR_001905
SNPlocs.Hsapiens.dbSNP144.GRCh37 (v 0.99.20)	Pagès <sup>64</sup>	<a href="https://bioconductor.org/packages/release/bioc/html/rtracklayer.html">https://bioconductor.org/packages/release/bioc/html/rtracklayer.html</a> ; RRID:SCR_021325
tidyverse (v 1.3.1)	Wickham et al. <sup>89</sup>	<a href="https://bioconductor.org/packages/release/data/annotation/html/SNPlocs.Hsapiens.dbSNP144.GRCh37.html">https://bioconductor.org/packages/release/data/annotation/html/SNPlocs.Hsapiens.dbSNP144.GRCh37.html</a>

bivariate local  $r_g$  analyses. Thus, bivariate local  $r_g$  analyses were only performed (i) if the gene expression trait (i.e. eQTL genes) exhibited a significant univariate local genetic signal and (ii) for pairs of traits (disease and gene expression) which both exhibited

a significant univariate local genetic signal. A cut-off of  $p < 0.05/92$  (the denominator represents the total number of tested genic regions) was used to determine univariate significance. A 100-kb window resulted in a total of 354 bivariate tests spanning 55



distinct genic regions. Bivariate results were corrected for multiple testing using two strategies: (i) a more lenient FDR correction and (ii) a more stringent Bonferroni correction ( $p < 0.05/n_{\text{tests}}$ , where the denominator represents the total number of bivariate tests). We discuss results passing  $FDR < 0.05$ , but we make the results of both correction strategies available (Supplementary Table 7, Supplementary Table 8).

We evaluated the effect of window size on bivariate correlations by re-running all analyses using a 50-kb window. Following filtering for significant univariate local genetic signal (as described above), a total of 267 bivariate tests were run spanning 50 distinct genic regions. We detected 110 significant bivariate local  $r_g$ s ( $FDR < 0.05$ ), 83 of which were also significant when using a 100-kb window (Supplementary Fig. 7). We observed strong positive Pearson correlations in local  $r_g$  coefficient and p-value estimates across the two window sizes, indicating that our results are robust to the choice of window size (Supplementary Fig. 7). Of note, p-value estimates between disease and gene expression traits tended to be lower when using the 50-kb window, as compared to the 100-kb window, as evidenced by the fitted line falling below the equivalent of  $y = x$ . This observation may be a reflection of stronger *cis*-eQTLs tending to have a smaller distance between SNP and gene<sup>42</sup>. In contrast, p-value estimates between two disease traits were comparable across the two window sizes.

Partial correlations were computed where three-way relationships were observed between 2 disease traits and an eQTL. The partial correlation reflects the correlation between 2 traits (e.g. disease X and Y) that can be explained by a third trait (e.g. eQTL, Z). Thus, a partial correlation approaching 0 suggests that trait Z captures an increasing proportion of the correlation between traits X and Y. Due to the three-way nature of the relationships, 3 possible conformations were possible (i.e.  $X \sim Y|Z$ ,  $X \sim Z|Y$  and  $Y \sim Z|X$ ); partial correlations were computed for all 3.

### Local multiple regression

For LD blocks with significant bivariate local  $r_g$  between one disease trait and  $\geq 2$  disease traits, multiple regression was used to determine the extent to which the genetic component of the outcome trait could be explained by the genetic components of multiple predictor traits. In those LD blocks where a three-way relationship was observed between 3 disease traits (e.g. X, Y and Z were all significantly correlated with one another), 3 possible conformations of 2 predictor models were possible (i.e.  $X \sim Y + Z$ ,  $Y \sim X + Z$ , and  $Z \sim X + Y$ ). In these situations, each disease trait was separately modelled as the outcome trait, resulting in 3 independent models within the LD block.

These analyses permitted exploration of the independent effects of predictor traits on the outcome trait, as well as possible confounding between predictors. A predictor trait was considered significant when  $p < 0.05$ .

### Sensitivity analysis using by-proxy cases

As UK Biobank (UKBB) by-proxy cases could potentially be mislabelled (i.e. parent of by-proxy case suffered from another type of dementia) and lead to spurious  $r_g$ s between neurodegenerative traits, we performed replication analyses using GWASs for AD<sup>27</sup> and PD that excluded UKBB by-proxy cases. LD blocks were filtered to include only those where significant bivariate local  $r_g$ s were observed between LBD and either by-proxy AD or by-proxy PD GWASs, in addition to between by-proxy AD and by-proxy PD GWASs. These criteria limited the number of LD blocks to 21. Bivariate local correlations were only performed for pairs of traits which both exhibited a significant univariate local genetic signal ( $p < 0.05/21$ , where the denominator represents the total number of tested loci), which resulted in a total of 10 bivariate tests spanning 6 distinct loci. Results are described in the Supplementary Note. We additionally performed multiple

regression in LD block 2351 using LBD as the outcome and AD and PD (both excluding UKBB by-proxy cases) as predictors. A predictor trait was considered significant when  $p < 0.05$ .

### R packages

All analyses were performed in R (v 4.0.5)<sup>70</sup>. As indicated in the accompanying GitHub repository (<https://github.com/RHReynolds/neurodegen-psych-local-corr>), all relevant packages were sourced from CRAN, Bioconductor (via BiocManager<sup>71</sup>) or directly from GitHub. Figures were produced using *circize*, *ggplot2* and *ggraph*<sup>72–74</sup>. All open-source software used in this paper is listed in Box 1.

### Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

### DATA AVAILABILITY

Analyses in this study relied on publicly available data, all of which are listed in Box 1. In the case of the PD GWAS without UK Biobank (UKBB) data, summary statistics were kindly provided by the International Parkinson Disease Genomics Consortium: <https://pdgenetics.org/>.

### CODE AVAILABILITY

Code used to pre-process GWASs, run genetic correlation analyses and to generate figures for the manuscript are available at: <https://github.com/RHReynolds/neurodegen-psych-local-corr> (<https://doi.org/10.5281/zenodo.6587707>). All other open-source software used in this paper is listed in Box 1.

Received: 16 March 2023; Accepted: 27 March 2023;

Published online: 28 April 2023

### REFERENCES

- Robinson, J. L. et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. *Brain J. Neurol.* **141**, 2181–2193 (2018).
- De Jager, P. L., Yang, H.-S. & Bennett, D. A. Deconstructing and targeting the genomic architecture of human neurodegeneration. *Nat. Neurosci.* **21**, 1310–1317 (2018).
- Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102 (2019).
- Guerreiro, R. et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. *Lancet Neurol.* **17**, 64–74 (2018).
- Chia, R. et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nat. Genet.* **53**, 294–303 (2021).
- Masters, C. L. et al. Alzheimer's disease. *Nat. Rev. Dis. Primer* **1**, 15056 (2015).
- Poewe, W. et al. Parkinson disease. *Nat. Rev. Dis. Primer* **3**, 17013 (2017).
- Kuring, J. K., Mathias, J. L. & Ward, L. Prevalence of Depression, Anxiety and PTSD in People with Dementia: a Systematic Review and Meta-Analysis. *Neuropsychol. Rev.* **28**, 393–416 (2018).
- Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D. & Leentjens, A. F. G. A systematic review of prevalence studies of depression in Parkinson's disease. *Mov. Disord. Off. J. Mov. Disord. Soc.* **23**, 183–189 (2008). quiz 313.
- Weintraub, D. et al. The neuropsychiatry of Parkinson's disease: advances and challenges. *Lancet Neurol.* **21**, 89–102 (2022).
- Ribe, A. R. et al. Long-term risk of dementia in persons with schizophrenia: A danish population-based cohort study. *JAMA Psychiatry* **72**, 1095–1101 (2015).
- Stroup, T. S. et al. Age-Specific Prevalence and Incidence of Dementia Diagnoses among Older US Adults with Schizophrenia. *JAMA Psychiatry* **78**, 632–641 (2021).
- Gustafsson, H., Nordström, A. & Nordström, P. Depression and subsequent risk of Parkinson disease A nationwide cohort study. *Neurology* **84**, 2422–2429 (2015).
- Kazmi, H. et al. Late onset depression: Dopaminergic deficit and clinical features of prodromal Parkinson's disease: A cross-sectional study. *J. Neurol. Neurosurg. Psychiatry* **92**, 158–164 (2021).
- Bellou, E., Stevenson-Hoare, J. & Escott-Price, V. Polygenic risk and pleiotropy in neurodegenerative diseases. *Neurobiol. Dis.* **142**, 104953 (2020).

16. Brainstorm Consortium. et al. Analysis of shared heritability in common disorders of the brain. *Science* **360**, eaap8757 (2018).
17. van Rheenen, W., Peyrot, W. J., Schork, A. J., Lee, S. H. & Wray, N. R. Genetic correlations of polygenic disease traits: from theory to practice. *Nat. Rev. Genet.* **20**, 567–581 (2019).
18. Gerring, Z. F., Thorp, J. G., Gamazon, E. R. & Derks, E. M. A Local Genetic Correlation Analysis Provides Biological Insights Into the Shared Genetic Architecture of Psychiatric and Substance Use Phenotypes. *Biol. Psychiatry* **92**, 583–591 (2022).
19. Stolp Andersen, M., Tan, M., Holtman, I. R., Hardy, J. & Pihlström, L. Dissecting the limited genetic overlap of Parkinson's and Alzheimer's disease. *Ann. Clin. Transl. Neurol.* 1–7 <https://doi.org/10.1002/acn3.51606> (2022).
20. Desikan, R. S. et al. Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. *Mol. Psychiatry* **20**, 1588–1595 (2015).
21. Drange, O. K. et al. Genetic overlap between alzheimer's disease and bipolar disorder implicates the MARK2 and VAC14 genes. *Front. Neurosci.* **13**, 1–11 (2019).
22. Lutz, M. W., Sprague, D., Barrera, J. & Chiba-Falek, O. Shared genetic etiology underlying Alzheimer's disease and major depressive disorder. *Transl. Psychiatry* **10**, 88 (2020).
23. Monereo-Sánchez, J. et al. Genetic Overlap Between Alzheimer's Disease and Depression Mapped Onto the Brain. *Front. Neurosci.* **15**, 653130 (2021).
24. Smeland, O. B. et al. Genome-wide Association Analysis of Parkinson's Disease and Schizophrenia Reveals Shared Genetic Architecture and Identifies Novel Risk Loci. *Biol. Psychiatry* **89**, 227–235 (2021).
25. GBD. 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Lond. Engl.* **396**, 1204–1222 (2020).
26. Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat. Genet.* **51**, 404–413 (2019).
27. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ , tau, immunity and lipid processing. *Nat. Genet.* **51**, 414–430 (2019).
28. Mullins, N. et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat. Genet.* **53**, 817–829 (2021).
29. Howard, D. M. et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat. Neurosci.* **22**, 343–352 (2019).
30. Pardiñas, A. F. et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat. Genet.* **50**, 381–389 (2018).
31. Werme, J., van der Sluis, S., Posthuma, D. & de Leeuw, C. A. An integrated framework for local genetic correlation analysis. *Nat. Genet.* **54**, 274–282 (2022).
32. Shi, H., Mancuso, N., Spendlove, S. & Pasaniuc, B. Local Genetic Correlation Gives Insights into the Shared Genetic Architecture of Complex Traits. *Am. J. Hum. Genet.* **101**, 737–751 (2017).
33. Zhang, Y. et al. SUPERGENOVA: local genetic correlation analysis reveals heterogeneous etiologic sharing of complex traits. *Genome Biol.* **22**, 262 (2021).
34. Jellinger, K. A. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies. *J. Neural Transm.* **125**, 615–650 (2018).
35. Erkinen, M. G., Kim, M. & Geschwind, M. D. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. *Cold Spring Harb. Perspect. Biol.* **10**, a033118 (2018).
36. Urs, N. M., Peterson, S. M. & Caron, M. G. New Concepts in Dopamine D2Receptor Biased Signaling and Implications for Schizophrenia Therapy. *Biol. Psychiatry* **81**, 78–85 (2017).
37. Underwood, R. et al. The GTPase Rab27b regulates the release, autophagic clearance, and toxicity of  $\alpha$ -synuclein. *J. Biol. Chem.* **295**, 8005–8016 (2020).
38. Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M. & Buckley, N. J. Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. *Front. Neurosci.* **13**, 164 (2019).
39. Bertram, L., McQueen, M. B., Mullin, K., Blacker, D. & Tanzi, R. E. Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. *Nat. Genet.* **39**, 17–23 (2007).
40. Singh, T. et al. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. *Nat. Neurosci.* **19**, 571–577 (2016).
41. Escott-Price, V. & Hardy, J. Genome-wide association studies for Alzheimer's disease: bigger is not always better. *Brain Commun.* **4**, fca125 (2022).
42. Vösa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nat. Genet.* **53**, 1300–1310 (2021).
43. Wang, D. et al. Comprehensive functional genomic resource and integrative model for the human brain. *Science* **362**, eaat8464 (2018).
44. Leeuw, C. de, Werme, J., Savage, J. E., Peyrot, W. J. & Posthuma, D. Reconsidering the validity of transcriptome-wide association studies. 2021.08.15.456414 Preprint at <https://doi.org/10.1101/2021.08.15.456414> (2022).
45. Yao, D. W., O'Connor, L. J., Price, A. L. & Gusev, A. Quantifying genetic effects on disease mediated by assayed gene expression levels. *Nat. Genet.* **52**, 626–633 (2020).
46. Ponce, G. et al. The ANKK1 kinase gene and psychiatric disorders. *Neurotox. Res.* **16**, 50–59 (2009).
47. Nho, K. et al. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. *BMC Med. Genomics* **10**, 29 (2017).
48. Zhou, X. et al. Non-coding variability at the APOE locus contributes to the Alzheimer's risk. *Nat. Commun.* **10**, 1–16 (2019).
49. Locascio, J. J. et al. Association between  $\alpha$ -synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. *Brain* **138**, 2659–2671 (2015).
50. Guerreiro, R. et al. Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. *Neurobiol. Aging* **38**, 214.e7–214.e10 (2016).
51. Moskvina, V. et al. Analysis of genome-wide association studies of alzheimer disease and of parkinson disease to determine if these 2 diseases share a common genetic risk. *JAMA Neurol.* **70**, 1268–1276 (2013).
52. Han, Z., Li, L., Huang, Y., Zhao, H. & Luo, Y. PBK/TOPK: A Therapeutic Target Worthy of Attention. *Cells* **10**, 371 (2021).
53. Dougherty, J. D. et al. PBK/TOPK, a Proliferating Neural Progenitor-Specific Mitogen-Activated Protein Kinase Kinase. *J. Neurosci.* **25**, 10773–10785 (2005).
54. Li, J. Y. et al. Scara5 Is a Ferritin Receptor Mediating Non-Transferrin Iron Delivery. *Dev. Cell* **16**, 35–46 (2009).
55. Crielard, B. J., Lammers, T. & Rivella, S. Targeting iron metabolism in drug discovery and delivery. *Nat. Rev. Drug Discov.* **16**, 400–423 (2017).
56. Gibson, J. et al. Assessing the presence of shared genetic architecture between Alzheimer's disease and major depressive disorder using genome-wide association data. *Transl. Psychiatry* **7**, e1094 (2017).
57. McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology* **89**, 88–100 (2017).
58. Ozaki, Y. et al. DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson's disease. *Acta Neurol. Scand.* **141**, 177–182 (2020).
59. Piggott, M. A. et al. Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline. *Synapse* **61**, 903–911 (2007).
60. Zerbino, D. R. et al. Ensembl 2018. *Nucleic Acids Res.* **46**, D754–D761 (2018).
61. Foo, J. N. et al. Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study. *JAMA Neurol.* **77**, 746–754 (2020).
62. Brown, B. C. Asian Genetic Epidemiology Network Type 2 Diabetes Consortium, Ye, C. J., Price, A. L. & Zaitlen, N. Transethnic Genetic-Correlation Estimates from Summary Statistics. *Am. J. Hum. Genet.* **99**, 76–88 (2016).
63. Broekema, R. V., Bakker, O. B. & Jonkers, I. H. A practical view of fine-mapping and gene prioritization in the post-genome-wide association era. *Open Biol.* **10**, 190221 (2020).
64. Pagès, H. SNPlocs.Hsapiens.dbSNP144.GRCh37: SNP locations for Homo sapiens (dbSNP Build 144). *R Package Version 09920* (2017) <https://bioconductor.org/packages/release/data/annotation/html/SNPlocs.Hsapiens.dbSNP144.GRCh37.html>.
65. Bulik-Sullivan, B. et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
66. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1236–1241 (2015).
67. Zheng, J. et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinform. Oxf. Engl.* **33**, 272–279 (2017).
68. International HapMap 3 Consortium. et al. Integrating common and rare genetic variation in diverse human populations. *Nature* **467**, 52–58 (2010).
69. 1000 Genomes Project Consortium. et al. A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
70. R Core Team. R: A language and environment for statistical computing. Preprint at (2021) <https://www.gbif.org/tool/81287/r-a-language-and-environment-for-statistical-computing>.
71. Morgan, M. Bioconductor: Access the Bioconductor Project Package Repository. Preprint at (2021).
72. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular visualization in R. *Bioinform. Oxf. Engl.* **30**, 2811–2812 (2014).
73. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*. (Springer-Verlag New York, 2016).
74. Pedersen, T. L. ggraph: An Implementation of Grammar of Graphics for Graphs and Networks. Preprint at (2021).
75. Wilke, C. O. cowplot: Streamlined Plot Theme and Plot Annotations for 'ggplot2'. Preprint at (2020).
76. Dowle, M. & Srinivasan, A. data.table: Extension of 'data.frame'. Preprint at (2021).



77. Corporation, M. & Weston, S. doSNOW: Foreach Parallel Adaptor for the 'snow' Package. Preprint at (2020).
78. Microsoft & Weston, S. foreach: Provides Foreach Looping Construct. Preprint at (2020).
79. Lawrence, M. et al. Software for Computing and Annotating Genomic Ranges. *PLoS Comput. Biol.* **9**, e1003118 (2013).
80. Clarke, E. & Sherrill-Mix, S. ggbeeswarm: Categorical Scatter (Violin Point) Plots. Preprint at (2017).
81. Kassambara, A. ggpubr: 'ggplot2' Based Publication Ready Plots. Preprint at (2020).
82. Warnes, G. R., Bolker, B. & Lumley, T. gtools: Various R Programming Tools. Preprint at (2021).
83. Müller, K. here: A Simpler Way to Find Your Files. Preprint at (2020).
84. Firke, S. janitor: Simple Tools for Examining and Cleaning Dirty Data. Preprint at (2021).
85. Schauburger, P. & Walker, A. openxlsx: Read, Write and Edit xlsx Files. Preprint at (2021).
86. Rinker, T. W. {qdapTools}: Tools to Accompany the qdap Package. Preprint at (2015).
87. Wickham, H. & Bryan, J. readxl: Read Excel Files. Preprint at (2019).
88. Lawrence, M., Gentleman, R. & Carey, V. rtracklayer: An R package for interfacing with genome browsers. *Bioinformatics* **25**, 1841–1842 (2009).
89. Wickham, H. et al. Welcome to the Tidyverse. *J. Open Source Softw.* **4**, 1686 (2019).

## ACKNOWLEDGEMENTS

We are grateful to Dr Cornelis Blauwendraat for feedback throughout this project. We would also like to thank the scientific community behind all the GWAS datasets, as well as data scientists developing the above-mentioned analysis tools, for making them publicly available and thus enabling the completion of this study. This research was funded in whole or in part by Aligning Science Across Parkinson's [Grant numbers: ASAP-000478 and ASAP-000509] through the Michael J. Fox Foundation for Parkinson's Research (MJFF). For the purpose of open access, the author has applied a CC BY public copyright license to all Author Accepted Manuscripts arising from this submission. AZW was supported through the award of a Clinical Research Fellowship funded by Eisai, Ltd and the Wolfson Foundation. SWS was supported in part by the Intramural Research Programme of the U.S. National Institutes of Health (National Institute of Neurological Disorders and Stroke; project number: 1Z1ANS003154). SAGT was supported by a Fonds de Recherche du Québec—Santé Junior 1 Award and by operational funds from the Institut de valorisation des données (IVADO). MR was supported through the award of a UKRI Medical Research Council Clinician Scientist Fellowship (MRC Grant Code: MR/N008324/1). J.H. was supported through the UKRI Medical Research Council (MRC Grant Code: MR/N026004/), the UK Dementia Research Institute, the Dolby Family Fund, and the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

## AUTHOR CONTRIBUTIONS

R.H.R. and A.Z.W. contributed equally to this work. R.H.R., S.A.G.T. and M.R. conceived and designed the study. R.H.R. and A.Z.W. analysed data and drafted the figures. F.L.D., M.S. and S.A.G.T. consulted on the statistical analysis. S.W.S. and M.R. provided clinical insight to data interpretation. R.H.R. wrote the initial paper. All authors contributed to the critical analysis and revision of the paper.

## COMPETING INTERESTS

A.Z.W. and S.W.S. declare no competing non-financial interests but the following competing financial interests: A.Z.W. served as a medical monitor for Neuroscience Trials Australia, receiving no personal compensation. S.W.S. serves on the scientific advisory council of the Lewy Body Dementia Association and receives grant support from Cerevel Therapeutics. R.H.R., F.L.D., M.S., J.H., S.A.G.T. and M.R. declare no competing interests.

## ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41531-023-00504-1>.

**Correspondence** and requests for materials should be addressed to Regina H. Reynolds or Mina Ryten.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023